NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPNT shares have decreased by 15.9% and is now trading at $9.13. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings data on Tuesday, May, 12th. The technology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.21. The technology company earned $4.28 million during the quarter, compared to analysts' expectations of $4.63 million. Opiant Pharmaceuticals had a net margin of 29.58% and a return on equity of 3.27%. View Opiant Pharmaceuticals' earnings history.

1 Wall Street analysts have issued twelve-month target prices for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 360.0% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

Media headlines about OPNT stock have trended negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned media headlines about the technology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news about Opiant Pharmaceuticals.

Opiant Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 15,000 shares, an increase of 87.5% from the June 15th total of 8,000 shares. Based on an average trading volume of 63,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.4% of the company's shares are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Rubicon Minerals (RBYCF), Fission Uranium (FCUUF), Amerigo Resources (ARREF), Mountain Province Diamonds (MPVDF), Atlatsa Resources (ATLRF), Pacific Booker Minerals (PBMLF), Santa Fe Gold (SFEG), Dakota Territory Resource (DTRC), Bullfrog Gold (BFGC), US Gold (USAU), Silver Bull Resources (SVBL), Quaterra Resources (QTRRF), Avalon Advanced Materials (AVLNF), Quantum Materials (QTMM) and Westwater Resources (WWR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Cyberark Software (CYBR), AT&T (T), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD) and Agenus (AGEN).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $9.13.

Opiant Pharmaceuticals has a market capitalization of $38.89 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

The official website for Opiant Pharmaceuticals is www.opiant.com.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]